

## SUPPLEMENTAL MATERIAL


Ising et al., <https://doi.org/10.1084/jem.20162125>

Figure S1. **All 9-mo-old mice express the scFvs.** (A–C) Immunoblot analysis shows expression of SC1 (A;  $n = 14$ ), SC3 (B;  $n = 16$ ), and control (C;  $n = 17$ ) scFv in cortex samples of all 9-mo-old P301S-tg mice analyzed in the study. (D) ELISA for unbound scFvs revealed similar scFv levels in hippocampal RAB fractions ( $n = 14$  for SC1 scFv and  $n = 16$  for SC3 scFv). (E) ELISA for tau-scFv complexes detected complexes in hippocampal RAB fractions for all 9-mo-old P301S-tg mice except for lysates from two AAV2/8 SC3 scFv-injected mice that were below the detection limit of the assay ( $n = 14$  for SC1 scFv and  $n = 16$  for SC3 scFv). All graphs represent means  $\pm$  SEM.




Figure S2. **AT8 staining correlates with salt-soluble and insoluble tau levels.** (A–C) Correlation analysis across all groups showed a highly significant negative correlation between htau levels in RAB fractions and positive AT8 staining in the hippocampus (A), whereas there was a positive correlation for htau levels in FA fractions (C) and no correlation at all for htau levels in RIPA fractions (B;  $n = 45$  in each analysis; 9-mo-old P301S-tg mice). Dashed lines represent 95% confidence intervals.




Figure S3. ScFvs bind to extracellular htau and inhibit tau uptake and seeding. (A) In vivo brain microdialysis followed by ELISA showed no significant differences (measured by one-way ANOVA) of extracellular htau levels between treatment groups in young (3–4.5 mo old) P301S-tg mice despite a trend to lower tau in SC3 scFv-treated mice ( $n = 9$  for control scFv,  $n = 7$  for SC1 scFv, and  $n = 8$  for SC3 scFv; ISF collected at a flow rate of 1  $\mu$ l/min). (B) Analysis of SC1 scFv- and SC3 scFv-treated mice showed a significant correlation between CSF and ISF htau levels in young P301S-tg mice ( $n = 6$  for SC1 scFv and  $n = 8$  for SC3 scFv). (C) No correlation between CSF and ISF htau levels was observed in young control scFv-treated P301S-tg mice ( $n = 8$  for control scFv). (D) Coimmunoprecipitation from ISF samples (collected at a flow rate of 0.5  $\mu$ l/min) with the anti-tau antibody HJ8.7 revealed coprecipitation of SC3 scFv with tau when analyzed by immunoblot. As a control, ISF sample buffer was mixed with the same concentration of purified SC3 scFv ( $n = 3$ ). (E) Fluorescently labeled tau uptake by N2a cells measured by flow cytometry revealed the potential of SC1 and SC3 scFv to block cellular uptake ( $n = 7$ ). (F) Fluorescently labeled tau uptake by primary cortical neuronal cultures measured by flow cytometry showed a significant inhibition of tau uptake in the presence of SC1 or SC3 scFvs ( $n = 4$ ). (G) Immunodepletion with SC1 or SC3 scFvs inhibits seeding activity of P301S-tg brain lysate when analyzed by measuring the FRET signal in the biosensor cells ( $n = 3$ ). Dashed lines in B and C represent 95% confidence intervals. All graphs are means  $\pm$  SEM. A and E–G were analyzed by one-way ANOVA, followed by Dunnett’s multiple comparison post hoc test comparing every column to control scFv/untreated: \*,  $P < 0.05$ ;  $***$ ,  $P < 0.001$ .